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IDENTIFICATION OF A UNIQUE CORE 
DOMAIN OF PAR-4 SUFFICIENT FOR 
SELECTIVE APOPTOSIS INDUCTION IN 
CANCER CELLS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims priority under 35 U.S.C. §119 to 
US. Provisional Application No. 60/430,669 entitled “Iden 
ti?cation of a Unique Core Domain of Par-4 Suf?cient for 
Selective Apoptosis Induction in Cancer Cells” ?led Dec. 4, 
2002, the entire content of Which is hereby incorporated by 
reference in its entirety. 
IDENTIFICATION OF FEDERAL FUNDING 
The present invention Was supported by NIH/NCI R01 
grants CA60872 and CA8451 1 , and therefore the government 
may have rights in the invention. 
FIELD OF THE INVENTION 
The present invention relates to prostate apoptosis 
response-4 (Par-4) mutants Which cause apoptosis in cancer 
cells Which are sensitive to Par-4 and also induce apoptosis in 
cancer cells Which are resistant to Par-4. The present inven 
tion also relates to methods of using the Par-4 mutant to treat 
certain cancers, as Well as to kits, vectors, and polypeptides 
for same. 
BACKGROUND OF THE INVENTION 
These mutants/Par-4 may be effective against all cancers. 
Cancer causes the death of hundreds of thousands of people 
each year. Treatments for cancer are not alWays effective. 
Cancer is dif?cult to treat because the development of 
cancer is a multistep process involving accumulation of mul 
tiple genetic aberrations. Most notable among such alter 
ations is the loss of apoptotic responses that normally serve as 
built in checkpoints against the emergence of cell populations 
With dysfunctional traits or the acquisition of prosurvival 
mechanisms that override the apoptotic signals. The loss of 
apoptotic mechanisms often results in abridged response to 
cancer therapy. Therefore, alternate or combinatorial 
approaches to kill the cancer cells and induce tumor regres 
sion are often actively pursued by researchers and physicians. 
Especially dif?cult to treat are those cancers Which are 
hormonally related. These cancers include prostate cancer 
and breast cancer. 
Prostate cancer is the most commonly diagnosed cancer in 
men and the second leading cause of cancer-related deaths in 
men in the United States. According to the American Cancer 
Society, about 198,100 neW cases of prostate cancer Will be 
diagnosed in the United States in 2001, and about 31,500 men 
Will die of the disease. See WWW.cancer.org/docroot/STT/ 
SHi0i2001. 
Prostate cancer cells fall into tWo types: androgen depen 
dent and androgen independent. Current treatment for pros 
tate cancer involves hormone treatments that remove test 
osterone, thereby killing the prostate cancer cells that are 
dependent on the hormone. HoWever, androgen independent 
cancer cells, Which are the cells responsible for prostate can 
cer spreading to other areas, are not killed by this treatment. 
About 30 percent of patients develop androgen independent 
prostate cancer Within three years of initial treatment, and 
patients With androgen independent cancer have a poor pro g 
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nosis in both localiZed and disseminated disease. Currently, 
there is a 34% chance of recurrence of prostate cancer. The 
median time to development of clinical metastasis after bio 
chemical recurrence is 8 years. Once treatment resistant 
metastatic disease is developed, the median time to death is an 
additional 5 years. Pound et al., JAMA (1999) 271: 1591-97. 
Another common cancer linked to hormone action is breast 
cancer. Current treatments for breast cancer include surgery 
to remove the cancer, radiation therapy, chemotherapy, 
peripheral stem cell transplantation, bone marroW transplan 
tation, hormonal therapy, and biological immunotherapy (us 
ing the immune system to ?ght cancer). 
Side effects of cancer therapies are often severe. They 
include nausea, vomiting, pain, poor appetite, Wasting, 
cachexia, diarrhea, burning in the stomach, stress, planter 
Warts, nerve death-neuropathy, radiation burns, fatigue, con 
stipation, anemia, anxiety, Weakened immune system, dry 
skin, bone marroW suppression and hair loss. 
An essential feature of anticancer strategies is the selective 
action against cancer cells, With little or no damage in?icted 
in normal cells. Identi?cation of molecules that can speci? 
cally target tumor cells, therefore, appropriately constitutes a 
signi?cant area of cancer research. Such molecules With 
selective action against tumor cells are valuable not only for 
their therapeutic potential; but also for their potential appli 
cations as tools for dissection of fundamental differences 
betWeen normal and cancer cells. Thus, the identi?cation of a 
molecule that can speci?cally target certain types of hormon 
ally linked cancers Would be extremely useful. 
SUMMARY OF THE INVENTION 
The present invention relates to the unexpected discovery 
of a unique domain of Par-4 (the SAC domain) Which can 
cause apoptosis in previously resistant cancer cells, but not in 
normal cells. Certain Par-4 mutants have been discovered to 
be useful in the treatment of cancer. 
An object of the present invention is to provide a modi?ed 
Par-4 comprising a substitution of least one amino acid resi 
due in the amino acid sequence of a precursor Par-4 in at least 
one position of naturally produced Par-4, Wherein the modi 
?ed Par-4 is effective in reducing the siZe of tumors resistant 
to Par-4. The modi?ed Par-4 is preferably 1-204, 137-221, 
137-213,137-198 or 137-195. 
Another object of the present invention provides an iso 
lated nucleic acid sequence fragment comprising at least 500 
contiguous nucleotides including a polymorphic site com 
prising a mutant of Par-4 selected from the group consisting 
of 1-204, 137-221, 137-213, 137-198 and 137-195. The 
invention also contemplates a recombinant DNA vector com 
prising one or more of these sequences operably linked to a 
transcription regulatory element. The invention further con 
templates a cell comprising a DNA vector Wherein the cell is 
preferably bacterial, fungal, plant, insect or mammalian. The 
invention further contemplates an isolated polypeptide com 
prising at least ?ve amino acid residues, Wherein the polypep 
tide has a sequence encoded by a nucleic acid contained in 
one or more sequences. 
Another object of the present invention provides a method 
of producing a polypeptide, comprising incubating a host cell 
comprising a nucleic acid encoding a polypeptide under con 
ditions that permit expression of the polypeptide. The method 
preferably comprises incubating a cell under conditions that 
permit expression of one or more polypeptides encoded by 
the nucleic acid. 
Another object of the present invention provides an anti 
body that speci?cally binds to at least one immunogenic 
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component, wherein the immunogenic component is encoded 
by one or more sequences of a Par-4 mutant. 
Another object of the present invention provides a method 
of screening for therapeutic agents comprising selecting a 
Par-4-associated speci?c sequence as a target sequence; con 
tacting a test compound With the target sequence; and select 
ing as candidate therapeutic agents those test compounds 
Which bind to the target sequence. 
The sequence is preferably a polypeptide encoded by a 
Par-4 mutant. The invention further contemplates a therapeu 
tic compound comprising an agent Which binds to one or 
more sequences of Par-4 mutant or a polypeptide encoded 
thereby. 
Another object of the present invention provides a kit for 
detecting the presence of a Par-4 mutant-associated nucleic 
acid in a sample comprising at least one container means 
having disposed therein at least a ?rst nucleic acid molecule 
of a Par-4 mutant. Preferably, at least one of the ?rst and 
second nucleic acid molecule includes a detectable label. 
Another object of the present invention provides a kit for 
detecting the presence a Par-4 mutant-associated polypeptide 
in a sample comprising at least one container means having 
disposed therein a ?rst antibody speci?c for at least one 
polypeptide of a Par-4 mutant. The kit preferably comprises a 
second antibody speci?c for at least one polypeptide of a 
Par-4 mutant. The kit preferably further comprises a means 
for detecting at least one of the ?rst and second antibodies. 
Another object of the present invention provides a method 
of treating cancer in a subject suffering therefrom, compris 
ing administering to the subject a Par-4 mutant, Wherein the 
administration of the Par-4 mutant causes reduction of tumors 
resistant to Par-4. The types of cancer treated include, but are 
not limited to, prostate cancer, breast cancer and lung cancer, 
and head and neck tumors. The subject is preferably a canine, 
a feline, an ovine, a primate, an equine, a porcine, a caprine, 
a camelid, an avian, a bovine, amphibian, ?sh or a murine 
organism. The subject is preferably a primate. The primate is 
preferably human. The Par-4 mutant is preferably 1-204, 
137-221, 137-213, 137-198 and 137-195. 
Another object of the present invention provides a pharma 
ceutical composition for the treatment of cancer, comprising 
an isolated and puri?ed Par-4 mutant and a pharmaceutically 
acceptable diluent, carrier or excipient. 
The mode of expression of the mutants in the cancer cells 
may include, but not limited to, the use of adenoviral vectors 
that can be injected intratumorally or intravenously, or as 
peptides or as fusion With other proteins or With antibodies. 
The use of these mutants can be combined With other forms of 
cancer treatment including, but not limited to, hormone 
therapy, chemotherapy or ioniZing radiation. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shoWs the nuclear localiZation of Par-4 correlates 
With apoptosis induction. Cells Were transfected With GFP 
Par-4 and treated With propidium iodide (PI) to detect nuclei. 
Intracellular localiZation of GFP-Par-4 Was recorded by con 
focal microscopy (A). GFP-Par-4 images are shoWn in the left 
panel, and the overlay of the GFP-Par-4 and PI images are 
shoWn in right panel. The yelloW color, resulting from the 
co-localiZation of GFP green ?uorescence With reddish-or 
ange PI staining (right panel), indicates the nuclear expres 
sion of Par-4. To determine percentage of apoptosis, cells 
Were transfected With GFP-Par-4 or GFP-vector as the con 
trol, and then subjected to DAPI staining. Apoptotic cells 
Were quanti?ed and expressed as a percentage of the total 
number of transfected cells (B). 
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FIG. 2 shoWs that the NLS2 is required for nuclear entry, 
inhibition of NF-B activity and induction of apoptosis. A 
schematic representation of full length Par-4, NLS1 and 
NLS2 is shoWn in panel A. PC-3 cells Were transiently trans 
fected With vector control, Par-4, NLS 1 or NLS2 or their 
GFP-tagged derivatives. The expression of endogenous Par-4 
(control), and ectopic Par-4, NLS1 and NLS2 proteins Were 
examined by Western blot analysis (B). Intracellular localiZa 
tion of NLS 1 and NLS2 (C), and their ability to induce 
apoptosis (E), Were examined as indicated in the description 
of FIG. 1. The apoptotic morphology of the NLS1 transfected 
cell inpanel CTo determines the inhibition of NF-B transcrip 
tional activity by Par-4 or its mutants (D). Cells Were trans 
fected for 48 hours With a Re1A reporter system and -galac 
tosidase plasmid together With vector, Par-4 or mutant 
constructs. Lysates Were subjected to luciferase assays, and 
luciferase activity Was normaliZed to the corresponding 
galactosidase activity. Inhibition of luciferase activity by 
Par-4 or its mutants is expressed relative to the activity noted 
With vector. 
FIG. 3 shoWs that the leucine Zipper domain is not essential 
for apoptosis. PC-3 cells Were transiently transfected With 
untagged or GFP-tagged derivatives of various C-terminal 
deletion mutants of Par-4 (A). After 48 hours, the cells Were 
examined for intracellular localiZation of the mutants (B), 
expression of the mutant proteins by Western blot analysis 
(C), inhibition of NF-B transcriptional activity (D), and apo 
ptosis (E), as seen in FIG. 1. To examine Fas translocation (F), 
PC-3 cells Were transiently transfected With untagged C-ter 
minal deletion mutants, and after 48 hours they Were stained 
With anti-Fas antibody. Alexa Fluor 488 green ?uorescence 
Was visualized by confocal microscopy. 
FIG. 4 shoWs the identi?cation of the core domain of Par-4 
Which is su?icient for apoptosis. Cells Were transiently trans 
fected With GFP-tagged derivatives of Par-4 deletion mutant 
137-332 or 148-332 (A) and examined for intracellular local 
iZation (B). Cells Were transiently transfected With various 
deletion mutants ofPar-4 137-204, 137-195, 137-190 or their 
GFP-tagged derivatives (C), and examined for expression by 
Western blot analysis (D), intracellular localiZation (E), inhi 
bition of NF-B activity (P), and apoptosis induction in the 
presence or absence of ectopic dnFADD (G), as seen in FIG. 
1. 
FIG. 5 shoWs that the core domain of Par-4 has an expanded 
but cancer-speci?c apoptotic ability. Various cell lines Were 
transiently transfected With GFP vector, GFP-Par-4 or GFP 
137-195, and examined for apoptosis in androgen-dependent 
or -independent prostate cancer cells or primary cells (A). 
LNCaP cells Were transiently transfected With GFP vector or 
GFP-137-195, With or Without dnFADD, and examined for 
apoptosis induction (B), as seen in FIG. 1. 
DETAILED DESCRIPTION OF THE INVENTION 
A. De?nitions 
In general, the terms in the present application are used 
consistently With the manner in Which those terms are under 
stood in the art. 
By “androgen-independent” is meant cancer cells or 
tumors Which do not require androgen to progress and/or 
proliferate. 
By “expression vector” is meant a DNA construct contain 
ing a DNA sequence Which is operably linked to a suitable 
control sequence capable of effecting the expression of said 
DNA in a suitable host. Such control sequences include a 
promoter to effect transcription, an optional operator 
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sequence to control such transcription, a sequence encoding 
suitable mRNA ribosome binding sites, and sequences Which 
control termination of transcription and translation. The vec 
tor may be a plasmid, a phage particle, or simply a potential 
genomic insert. Once transformed into a suitable host, the 
vector may replicate and function independently of the host 
genome, or may, in some instances, integrate into the genome 
itself. The invention is intended to include such other forms of 
expression vectors Which serve equivalent functions and 
Which are, or become, knoWn in the art. 
Host cells are transformed or transfected With vectors con 
structed using recombinant DNA techniques. Such trans 
formed host cells are capable of either replicating vectors 
encoding the carbonyl hydrolase mutants or expressing the 
desired carbonyl hydrolase mutant. In the case of vectors 
Which encode the pre or prepro form of the carbonyl hydro 
lase mutant, such mutants, When expressed, are typically 
secreted from the host cell into the host cell medium. 
By “operably linked” is meant the relationship betWeen 
tWo DNA regions such that they are functionally related to 
each other. For example, a presequence is operably linked to 
a peptide if it functions as a signal sequence, participating in 
the secretion of the mature form of the protein most probably 
involving cleavage of the signal sequence. A promoter is 
operably linked to a coding sequence if it controls the tran 
scription of the sequence; a ribosome binding site is operably 
linked to a coding sequence if it is positioned so as to permit 
translation. 
The genes encoding the naturally-occurring Par-4 may be 
obtained in accord With the general methods described by 
methods knoWn in the art. 
The cloned Par-4 may then be used to transfect a host cell 
in order to express the Par-4. The Par-4 gene may then be 
ligated into a high copy number plasmid. This plasmid repli 
cates in hosts in the sense that it contains the Well-knoWn 
elements necessary for plasmid replication; a promoter oper 
ably linked to the gene in question (Which may be supplied as 
the gene’s oWn homologous promoter if it is recognized, i.e., 
transcribed, by the host), a transcription termination and 
polyadenylation region (necessary for stability of the mRNA 
transcribed by the host from the Par-4 gene in certain eucary 
otic host cells) Which is exogenous or is supplied by the 
endogenous terminator region of the Par-4 gene and, desir 
ably, a selection gene such as an antibiotic resistance gene 
that enables continuous cultural maintenance of plasmid 
infected host cells by groWth in antibiotic-containing media. 
High copy number plasmids also contain an origin of repli 
cation for the host, thereby enabling large numbers of plas 
mids to be generated in the cytoplasm Without chromosomal 
limitations. HoWever, it is Within the scope herein to integrate 
multiple copies of the Par-4 gene into host genome. This is 
facilitated by procaryotic and eucaryotic organisms Which are 
particularly susceptible to homologous recombination. 
II. Introduction 
The inventors have discovered that various in vitro muta 
tions involving the deletion of one or more amino acids Within 
a Par-4 amino acid sequence can confer advantageous prop 
erties to such mutants especially With regard to inducing 
cancer cell death. 
Speci?cally, the Par-4 gene has been mutated by modifying 
the DNA to encode the substitution of one or more amino 
acids at various amino acid residues Within the mature form of 
the Par-4 molecule. 
The inventors have discovered that nuclear translocation of 
Par-4 correlates With susceptibility to apoptosis. Speci?cally, 
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a unique core domain of Par-4 Which is required for the 
induction of apoptosis has been discovered. This core domain 
induces apoptosis in cancer cells, but not in normal cells. 
The inventors have discovered the folloWing important 
mutants of Par-4. In summary, the folloWing mutants have 
been unexpectedly found to induce apoptosis in cancer cells 
Which are sensitive or resistant to full-length Par-4 (SEQ ID 
NO: 1), but do not induce apoptosis in normal cells. They are 
1-204, 137-221, 137-213, 137-198 and 137-195 of SEQ ID 
NO: 1. One advantage of these mutants is that they de?ne the 
active domain of Par-4 and localiZe that active domain to the 
59 amino acid region betWeen amino acid 137 and 195 of 
Par-4 (the Wild type Par-4 has 332 amino acids, SEQ ID NO: 
1). This 59 amino acid region contains a nuclear localiZation 
sequence that alloWs entry of the protein into the nucleus and 
tWo phosphorylation sites. Thus, these mutants are useful in 
inducing apoptosis in cancer cells. 
III. Par-4 Mechanism of Action 
The Par-4 gene, ?rst identi?ed by the inventors (see Sells et 
al., 1994) in prostate cancer cells undergoing apoptosis, 
encodes a proapoptotic protein that is remarkably effective in 
inducing cancer cell apopto sis and tumor regression in animal 
models. The inventors have found that Par-4 induces apopto 
sis in androgen independent prostate cancer cells, such as 
PC3 and DU145, and in Ras transformed mouse ?broblasts. 
HoWever, Par-4 does not induce apoptosis in androgen depen 
dent prostate cancer cells, such as LNCaP, in immortalized 
cells or in primary cultures of normal prostate epithelial and 
stromal cells. 
Overexpression of Par-4 in cells that are resistant to direct 
apoptosis by Par-4 renders the cells supersensitive to a broad 
range of apoptotic insults, including chemotherapeutic 
agents, TNF, or ioniZing radiation. The Par-4 gene maps to 
human chromosome 12q21, Which is often deleted in pancre 
atic cancer. Par-4 expression is doWnregulated in renal cell 
carcinoma relative to the normal proximal tubular cell com 
partment. Moreover, oncogenes such as Ras, Raf or Src 
doWnregulate Par-4 expression, and restoration of Par-4 level 
results in inhibition of oncogene induced transformation of 
cells. Inhibition of Par-4 With a dominant negative mutant or 
an antisense oligodeoxynucleotide has been found to protect 
neuronal cells from apoptosis in cell culture and animal mod 
els of neurodegenerative diseases. 
The transcription activity of NFkB is an essential anti 
apoptotic target of Par-4. NfkB plays a crucial role in in?am 
mation and immune response by activating the transcription 
of a number of key cytokines and cytokine receptors, antago 
niZing apoptosis by upregulation of inhibitor of apoptosis 
proteins and supporting cell proliferation. More importantly, 
NFkB plays an essential role in oncogenesis and in the resis 
tance of tumor cells to ioniZing radiation and chemotherapy. 
The transcription potential of NFkB, a heterodimer betWeen 
subunits p65 (RelA) and p50, is fully activated by transloca 
tion to the nucleus and phosphorylation of RelA. Par-4 inhib 
its Ras or Raf induced NFkB transcriptional activity in mouse 
?broblast cells and the constitutively activated NFkB tran 
scription activity in androgen independent prostate cancer 
cell lines. 
Previous studies indicated that the inhibitory effect of Par-4 
is targeted toWard the transactivation domain (TA1) of the 
RelA subunit of NFkB. Inhibition of NFkB activity by super 
repressor IkBa is suf?cient to induce apoptosis in NIH 3T3 
cells expressing oncogenic Ras. Overexpression of Par-4 is 
suf?cient to induce apoptosis in these cells. HoWever, in 
androgen independent prostate cancer cells, inhibition of 
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NFkB is not suf?cient to induce apoptosis or to cause tumor 
regression, suggesting that Par-4 may also activate a prodeath 
pathway in these cells. 
Par-4 was found to induce apoptosis by coparallel activa 
tion of the FasL/Fas pathway and inhibition of NFkB tran 
scription activity in the androgen independent cells. Fas 
(CD95) is a member of the TNFR family of death receptors 
that is activated by binding to FasL leading to the formation of 
DISC. This complex is composed of the trimerized Fas, 
FADD and procaspase 8 and its formation leads to the acti 
vation of caspase8 and to the induction of downstream 
caspases and apoptosis. Speci?cally, Par-4 activates the Fas 
pathway by promoting the Fas/FasL translocation to the cell 
membrane and by protecting the Fas apoptotic pathway from 
the inhibitory effects of zPKC. Activation of the Fas pathway 
and inhibition of NFkB activity are both essential for apop 
tosis induction by Par-4 in androgen independent prostate 
cancer cells. 
Despite the advances made in understanding the mecha 
nism of action of Par-4, the active domains of Par-4, as well as 
its functional localization, were largely unknown. The amino 
acid sequence of the Par-4 protein predicts a leucine zipper 
domain at its C-terminal end, between amino acids 292 and 
332. This domain is involved in binding to all currently 
known partners of Par-4, including WT1, zPKC, p62 and Dlk. 
The leucine zipper domain is required for sensitization to 
apoptosis by Par-4. A deletion mutant of Par-4 lacking the 
leucine zipper domain (DZip) is unable to sensitize cells to 
apoptotic stimuli. Moreover, PC12 cells expressing DZip are 
insensitive to Ab142 or withdrawal of trophic factors. These 
?ndings indicate that the C-terminal leucine zipper domain is 
indispensable for the apoptosis sensitizing function of Par-4 
(see Sells et al. 1997). 
Par-4 contains two putative nuclear localization sequences, 
NLS1 at amino acids 20 to 25 and NLS2 at amino acids 
137-153, both in the N terminal half of Par-4. In most tissues 
and cell types, endogenous Par-4 is localized in the cyto 
plasm. Par-4 is cytoplasmic in the immortalized ?broblast 
cells NIH 3T3, and deletion of the ?rst 68 amino acids includ 
ing NLS1 does not affect the apoptosis sensitizing function of 
Par-4. The following observations support a nuclear function 
for Par-4: (1) the presence of a bipartite nuclear localization 
sequence (NLS2); (2) the ability of Par-4 to inhibit RelA 
transcription activity; (3) direct binding to the nuclear pro 
teins Dlk and WT1; and (4) binding to WT1 and inhibition of 
the bcl2 promoter. 
Recent studies indicate that the leucine zipper domain pro 
tein Par-4 induces apoptosis in certain cancer cells by activa 
tion of the Fas prodeath receptor pathway and coparallel 
inhibition of the cell survival NFkB transcription activity. 
However, the intracellular localization or functional domains 
of Par-4 involved in apoptosis remained unknown. 
In the present invention, structure function analysis indi 
cated that inhibition of NFkB transcription activity and apo 
ptosis are dependent on Par-4 translocation to the nucleus via 
a bipartite nuclear localization signal sequence NLS2. Cancer 
cells that were resistant to Par-4 induced apoptosis retained 
Par-4 in the cytoplasm. A 59 amino acid core from amino 
acids 137 to 195 that included NLS2, but not the C-terminal 
leucine zipper domain of Par-4, was necessary and su?icient 
to induce Fas pathway activation, inhibition of nuclear NFkB 
transcription activity and apoptosis. Most importantly, this 
core domain of Par-4 had an expanded apoptotic target range 
extending to the cancer cells that were resistant to Par-4, but 
not to normal cells. These ?ndings have identi?ed a unique 
‘death domain’ that is selective for apoptosis induction in 
cancer cells, (i.e., the SAC domain), which holds promise for 
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identifying key differences between cancer and normal cells, 
and for molecular therapy of cancer. 
Thus, the present invention indicates that Par-4 transloca 
tion into the nucleus is essential for induction of apoptosis. 
The NLS2 domain of Par-4 is essential for nuclear transloca 
tion, and resistance to apoptosis was noted in cells that did not 
translocate Par-4 to the nucleus or with Par-4 constructs that 
lacked an intact NLS2 domain. Moreover, nuclear transloca 
tion was essential for inhibition of RelA transcription activity 
by Par-4. Because inhibition of RelA activity is critical for 
apoptosis by Par-4, these observations suggest that Par-4 has 
a nuclear function that includes RelA transcription inhibition 
and induction of apoptosis. Further, the deletion analysis 
identi?ed the 59 amino acid core domain of Par-4 that con 
stitutes a minimal region of Par-4 which is suf?cient for 
apoptosis. This core domain translocates into the nucleus in 
both cancer and normal or immortalized cells, but is selective 
in inducing apoptosis of the cancer cells, regardless of 
whether or not they are sensitive to wild type Par-4. This core 
domain is 100% conserved in rat, mouse and human Par-4. 
Because this domain does not induce apoptosis in normal 
cells but induces apoptosis in diverse cancer cells, it has been 
designated Selective Apoptosis induction of Cancer cells 
(i.e., SAC domain). This domain does not resemble the death 
domains (DD) or death effector domains (DED) of other 
proapoptotic proteins. Unlike the previously characterized 
DD/DED, the SAC domain speci?cally induces apoptosis in 
cancer cells and not normal cells. Because Par-4 causes 
remarkable regression of solid tumors by apoptosis driven by 
Fas pro-death pathway activation and inhibition of NFkB 
activity, the SAC domain, which utilizes a similar mechanism 
of apoptosis, also causes tumor regression by apoptosis. The 
cancer speci?c apoptotic potential of the SAC domain renders 
it a promising candidate for directed molecular therapeutics 
of cancer. 
The leucine zipper domain of Par-4 is necessary for apop 
tosis sensitization of cells to diverse apoptotic insults (see 
Sells et al., 1997). This sensitizing action is regulated by Par-4 
interaction via its leucine zipper domain, with WT1, DLK, 
zPKC, and p62. Depending on the partner and the cellular 
context, the apoptosis sensitizing function of Par-4 is imple 
mented in the cytoplasm when regulated by DLK, zPKC, and 
p62, or in the nucleus when regulated by WT1. The ?ndings 
of the present invention suggest that the leucine zipper 
domain of Par-4 is not essential for apoptosis induced by 
Par-4 acting alone. Thus, the interactive partners identi?ed 
thus far might not be involved in regulation of the direct 
apoptotic action of Par-4, unless they also bind to the core 
domain. In addition, the deletion of the leucine zipper domain 
resulted in increased nuclear translocation of Par-4. Because 
the leucine zipper domain contains a putative nuclear exclu 
sion sequence (amino acids 291 to 302) that may compete 
with NLS2 sequence, it is believed that the distribution of 
Par-4 in the nuclear versus cytoplasmic compartments may be 
regulated by the relative activities of the NES and NLS2 
domains. 
In summary, by deletion analysis, the present invention 
provides a unique core domain of Par-4 that is essential for 
nuclear entry, Fas pro-death pathway activation, inhibition of 
NFkB activity and induction of apoptosis. This domain 
extends the susceptibility spectrum of Par-4 to diverse cancer 
cells, regardless of whether they are susceptible or resistant to 
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Par-4. Because this domain shows selective action against 
cancer cells but not normal cells, it has both academic and 
therapeutic applications. 
IV. Mutants of Par-4 
The inventors have discovered the following important 
mutants of Par-4. In summary, the following mutants have 
been unexpectedly found to induce apoptosis in cancer cells 
which are sensitive or resistant to full-length Par-4, but do not 
induce apoptosis in normal cells. They are 1-204, 137-221, 
137-213, 137-198 and 137-195. One advantage of these 
mutants is that they de?ne the active domain of Par-4 and 
localize that active domain to the 59 amino acid region 
between amino acid 137 and 195 of Par-4 (the wild type Par-4 
has 332 amino acids). This 59 amino acid region contains a 
nuclear localization sequence that allows entry of the protein 
into the nucleus and two phosphorylatron sites. Thus, these 
mutants are useful in inducing apoptosis in cancer cells. 
Those of ordinary skill in the art will recognize that the 
particular methods of polymorphism identi?cation described 
herein are not intended to be limiting of the present invention. 
Any of the variety of other known techniques, such as, for 
example, RNA-DNA hybrid cleavage using RNase A, mis 
match detection using heteroduplex analysis, denaturing gra 
dient electrophoresis, and chemical cleavage heteroduplex 
DNA (see, Current Protocols in Human Genetics, Volume 1, 
Chapter 7, John Wiley and Sons, 1995). 
As described above, the present invention relates to Par-4 
sequences, RNA, fragments of the genomic, cDNA, or 
nucleic acids comprising 5, 10, 15, 30, 60, 100, 200, 500 or 
more contiguous nucleotides, and the complements thereof. 
Closely related variants are also included as part of this inven 
tion, as well as recombinant nucleic acids comprising at least 
50, 60, 70, 80, or 90% of the nucleic acids described above 
which would be identical to the Par-4 nucleic acids except for 
one or a few substitutions, deletions, or additions. 
Further, the nucleic acids of this invention include the 
adjacent chromosomal regions of Par-4 required for accurate 
expression of the respective gene. In a preferred embodiment, 
the present invention is directed to at least 15 contiguous 
nucleotides of the nucleic acid sequence of Par-4. 
It is understood that, as a result of the degeneracy of the 
genetic code, many nucleic acid sequences are possible which 
encode a Par-4-like protein orpolypeptide. Some of these will 
have little homology to the nucleotide sequences of any 
known or naturally-occurring Par-4-like gene but can be used 
to produce the proteins and polypeptides of this invention by 
selection of combinations of nucleotide triplets based on 
codon choices. Such variants, while not hybridizable to a 
naturally occurring Par-4 gene, are contemplated within this 
invention. 
The nucleic acids described herein are used in the methods 
of the present 30 invention for production of proteins or 
polypeptides, through incorporation into cells, tissues, or 
organisms. In one embodiment, DNA containing all or part of 
the coding sequence for a Par-4 polypeptide, or DNA which 
hybridizes to DNA, is incorporated into a vector for expres 
sion of the encoded polypeptide in suitable host cells. The 
encoded polypeptide consisting of Par-4, or its functional 
equivalent is capable of normal activity. The term “vector” as 
used herein refers to a nucleic acid molecule capable of trans 
porting another nucleic acid to which it has been linked. A 
vector, for example, can be a plasmid. 
Nucleic acids referred to herein as “isolated” are nucleic 
acids separated away from the nucleic acids of the genomic 
DNA or cellular RNA of their source of origin (e.g., as it 
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exists in cells or in a mixture of nucleic acids such as a 
library), and may have undergone further processing. “Iso 
lated”, as used herein, refers to nucleic or amino acid 
sequences that are at least 60% free, preferably 75% free, and 
most preferably 90% free from other components with which 
they are naturally associated. “Isolated” nucleic acids (poly 
nucleotides) include nucleic acids obtained by methods 
described herein, similar methods or other suitable methods, 
including essentially pure nucleic acids, nucleic acids pro 
duced by chemical synthesis, by combinations of biological 
and chemical methods, and recombinant nucleic acids which 
are isolated. Nucleic acids referred to herein as “recombi 
nant” are nucleic acids which have been produced by recom 
binant DNA methodology, including those nucleic acids that 
are generated by procedures which rely upon a method of 
arti?cial recombination, such as the polymerase chain reac 
tion (PCR) and/or cloning into a vector using restriction 
enzymes. “Recombinant” nucleic acids are also those that 
result from recombination events that occur through the natu 
ral mechanisms of cells, but are selected for after the intro 
duction to the cells of nucleic acids designed to allow or make 
probable a desired recombination event. Portions of the iso 
lated nucleic acids which code for polypeptides having a 
certain function can be identi?ed and isolated by methods 
known in the art. 
A further embodiment of the invention is antisense nucleic 
acids or oligonucleotides which are complementary, in whole 
or in part, to a target molecule comprising a sense strand, and 
can hybridize with the target molecule. The target can be 
DNA, or its RNA counterpart (i.e., wherein T residues of the 
DNA are U residues in the RNA counterpart). When intro 
duced into a cell, antisense nucleic acids or oligonucleotides 
can inhibit the expression of the gene encoded by the sense 
strand or the mRNA transcribed from the sense strand. Anti 
sense nucleic acids can be produced by standard techniques 
known in the art. 
In a particular embodiment, an antisense nucleic acid or 
oligonucleotide is wholly or partially complementary to and 
can hybridize with a target nucleic acid (either DNA or RNA), 
wherein the target nucleic acid can hybridize to a nucleic acid 
having the sequence of the complement of the strand. For 
example, an antisense nucleic acid or oligonucleotide can be 
complementary to a target nucleic acid having the sequence 
shown as the strand of the open reading frame or nucleic acid 
encoding a functional equivalent of Par-4, or to a portion of 
these nucleic acids suf?cient to allow hybridization. A por 
tion, for example, a sequence of 16 nucleotides could be 
suf?cient to inhibit expression of the protein. Or, an antisense 
nucleic acid or oligonucleotide complementary to 5' or 3' 
untranslated regions, or overlapping the translation initiation 
codon (5' untranslated and translated regions), of the Par-4 
gene, or a gene encoding a functional equivalent can also be 
effective. In another embodiment, the antisense nucleic acid 
is wholly or partially complementary to and can hybridize 
with a target nucleic acid which encodes a Par-4 polypeptide. 
In addition to the antisense nucleic acids of the invention, 
oligonucleotides can be constructed which will bind to 
duplex nucleic acid either in the gene or the DNA:RNA 
complex of transcription, to form a stable triple helix-con 
taining or triplex nucleic acid to inhibit transcription and/or 
expression of a gene encoding Par-4, or its functional equiva 
lent. Such oligonucleotides of the invention are constructed 
using the base-pairing rules of triple helix formation and the 
nucleotide sequence of the gene or mRNA for Par-4. These 
oligonucleotides can block Par-4-type activity in a number of 
ways, including prevention of transcription of the Par-4 gene 
or by binding to mRNA as it is transcribed by the gene. 
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The invention also relates to proteins or polypeptides 
encoded by the nucleic acids described herein. The proteins 
and polypeptides of this invention can be isolated and/or 
recombinant. Proteins or polypeptides referred to herein as 
“isolated” are proteins or polypeptides puri?ed to a state 
beyond that in Which they exist in cells. In a preferred 
embodiment, they are at least 10% pure; i.e., most preferably 
they are substantially puri?ed to 80 or 90% purity. “Isolated” 
proteins or polypeptides include proteins or polypeptides 
obtained by methods described infra, similar methods or 
other suitable methods, and include essentially pure proteins 
orpolypeptides, proteins orpolypeptides produced by chemi 
cal synthesis or by combinations of biological and chemical 
methods, and recombinant proteins or polypeptides Which are 
isolated. Proteins or polypeptides referred to herein as 
“recombinant” are proteins or polypeptides produced by the 
expression of recombinant nucleic acids. In a preferred 
embodiment, the protein or portion thereof has at least one 
function characteristic of a Par-4 protein or polypeptide. 
A “portion” as used herein With regard to a protein or 
polypeptide, refers to fragments of that protein or polypep 
tide. The fragments can range in size from 5 amino acid 
residues to all but one residue of the entire protein sequence. 
Thus, a portion or fragment can be at least 5, 5-50, 50-100, 
100-200, 200-400, 400-800, or more 20 consecutive amino 
acid residues of a Par-4 protein or polypeptide, for example, 
Table 2, or a variant thereof. The invention also relates to 
isolated, synthesized and/or recombinant portions or frag 
ments of a Par-4 protein or polypeptide as described above. 
Polypeptide fragments of the enzyme can be made Which 
have full or partial function on their oWn, or Which When 
mixed together (though fully, partially, or nonfunctional 
alone), spontaneously assemble With one or more other 
polypeptides to reconstitute a functional protein having at 
least one functional characteristic of a Par-4 protein of this 
invention. 
The invention also concerns the use of the nucleotide 
sequence of the nucleic 30 acids of this invention to identify 
DNA probes for Par-4 genes, PCR primers to amplify Par-4 
genes, and regulatory elements of the Par-4 genes. 
The nucleic acids of this invention can be produced in large 
quantities by replication in a suitable host cell. Natural or 
synthetic nucleic acid fragments, comprising at least ten con 
tiguous bases coding for a desired peptide or polypeptide can 
be incorporated into recombinant nucleic acid constructs, 
usually DNA constructs, capable of introduction into and 
replication in a prokaryotic or eukaryotic cell. Usually the 
nucleic acid constructs Will be suitable for replication in a 
unicellular host, such as yeast or bacteria, but may also be 
intended for introduction to (With and Without integration 
Within the genome) cultured mammalian or plant or other 
eukaryotic cells, cell lines, tissues, or organisms. The puri? 
cation of nucleic acids produced by the methods of the present 
invention is described, for example, in Sambrook et al, 
Molecular Cloning. A Laboratory Manual, 2nd Ed. (Cold 
Spring Harbor Laboratory, Cold Spring Harbor, NY (1989) 
or Ausubel et al, Current Protocols in Molecular Biology, J. 
Wiley and Sons, NY (1992). 
The nucleic acids of the present invention can also be 
produced by chemical synthesis, e. g., by the pho sphoramidite 
method described by Beaucage et al., Tetra. Letts., 22:1859 
1862 (1981) or the triester method according to Matteucci et 
al., .1. Am. Chem. Soc, 103:3 185 (1981), and can performed 
on commercial, automated oligonucleotide synthesizers. A 
double-stranded fragment may be obtained from the single 
stranded product of chemical synthesis either by synthesizing 
the complementary strand and annealing the strands together 
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under appropriate conditions or by adding the complemen 
tary strand using DNA polymerase With an appropriate 
primer sequence. 
These nucleic acids can encode full-length variant forms of 
proteins as Well as the naturally-occurring protein. The vari 
ant proteins (Which could be especially useful for detection 
and treatment of disorders) Will have the variant amino acid 
sequences encoded by polymorphisms, When said polymor 
phisms are read so as to be in-frame With the full-length 
coding sequence of Which it is a component. 
Nucleic acid constructs prepared for introduction into a 
prokaryotic or eukaryotic host Will comprise a replication 
system recognized by the ho st, including the intended nucleic 
acid fragment encoding the selected protein or polypeptide, 
and Will preferably also include transcription and transla 
tional initiation regulatory sequences operably linked to the 
protein encoding segment. Expression vectors may include, 
for example, an origin of replication or autonomously repli 
cating sequence (ARS) and expression control sequences, a 
promoter, an enhancer and necessary processing information 
sites, such as ribosome-binding sites, RNA splice sites, poly 
adenylation sites, transcriptional terminator sequences, and 
mRNA stabilizing sequences. Secretion signals are also 
included, Where appropriate, Whether from a native Par-4 
protein or from other receptors or from secreted proteins of 
the same or related species, Which alloW the protein to cross 
and/or lodge in cell membranes, and thus attain its functional 
topology, or be secreted from the cell. Such vectors may be 
prepared by means of standard recombinant techniques Well 
knoWn in the art and discussed, for example, in Sambrook et 
al., Molecular Cloning. A Laboratory Manual, 2nd Ed. (Cold 
Spring Harbor Laboratory, Cold Spring Harbor, NY. (1989) 
or Ausubel et al., Current Protocols in Molecular Biology, J. 
Wiley and Sons, NY (1992). 
An appropriate promoter and other necessary vector 
sequences Will be selected 15 so as to be functional in the host, 
and Will include, When appropriate, those naturally associated 
With Par-4 genes. Examples of Workable combinations of cell 
lines and expression vectors are described in Sambrook et al., 
Molecular Cloning A Laboratory Manual, 2nd Ed. (Cold 
Spring Harbor Laboratory, Cold Spring Harbor, NY. (1989) 
or Ausubel et al., Current Protocols in Molecular Biology, J. 
Wiley and Sons, NY (1992). Many useful vectors are knoWn 
in the art and can be obtained from such vendors as Stratagene 
(supra), NeW England BioLabs, Beverly, Mass., USA, 
Promega Biotech, and otherbiotechnology product suppliers. 
Promoters such as the trp, lac and phage promoters, tRNA 
promoters and glycolytic enzyme promoters may be used in 
prokaryotic hosts. Useful yeast promoters include promoter 
regions for metallothionein, 3-phosphoglycerate kinase or 
other glycolytic enzymes such as enolase or glyceraldehyde 
3-phosphate dehydrogenase, enzymes responsible for mal 
tose and galactose utilization, and others. In addition, the 
construct may be joined to an ampli?able gene so that mul 
tiple copies of the gene may be made. For appropriate 
enhancer and other expression control sequences, see also 
Enhancers and Eukaryotic Gene Expression, Cold Spring 
Harbor Press, Cold Spring Harbor, NY (1983). While such 
expression vectors may replicate autonomously, they may 
also replicate by being inserted into the genome of the host 
cell, by methods Well knoWn in the art. 
Expression and cloning vectors Will likely contain a select 
able marker, a gene encoding a protein necessary for survival 
or groWth of a host cell transformed With the vector. The 
presence of this gene ensures groWth of only those host cells 
Which express the inserts. Typical selection genes encode 
proteins that a) confer resistance to antibiotics or other toxic 
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substances, e.g. ampicillin, neomycin, methotrexate, b) 
complement auxotrophic de?ciencies, or c) supply critical 
nutrients not available from complex media, e.g., the gene 
encoding D-alanine racemase for Bacilli. The choice of the 
proper selectable marker Will depend on the host cell, and 
appropriate markers for different hosts are Well knoWn in the 
art. 
The vectors containing the nucleic acids of interest can be 
transcribed in vitro, and the resulting RNA introduced into the 
host cell by Well-knoWn methods, e.g., by injection (see, 
Kubo et al., FEBS Letts. 241:119 (1988)), or the vectors can 
be introduced directly into host cells by methods Well knoWn 
in the art, Which vary depending on the type of cellular host, 
including electroporation; transfection employing calcium 
chloride, rubidium chloride, calcium phosphate, DEAE-dex 
tran, or other sub stances; microproj ectile bombardment; lipo 
fection; infection (Where the vector is an infectious agent, 
such as a retroviral genome); and other methods. See, Sam 
brook et al., 1989 and Ausubel et al., 1992. The introduction 
of the nucleic acids into the host cell by any method knoWn in 
the art, including those described above, Will be referred to 
herein as “transformation.” The cells into Which have been 
introduced nucleic acids described above are meant to also 
include the progeny of such cells. 
Large quantities of the nucleic acids and proteins of the 
present invention may be prepared by expressing the Par-4 
nucleic acids or portions thereof in vectors or other expres 
sion vehicles in compatible prokaryotic or eukaryotic host 
cells. The most commonly used prokaryotic hosts are strains 
of Escherichia coli, although other prokaryotes, such as 
Bacillus subtilis or Pseudomonas may also be used. 
Mammalian or other eukaryotic host cells, such as those of 
yeast, ?lamentous fungi, plant, insect, or amphibian or avian 
species, may also be useful for production of the proteins of 
the present invention. Propagation of mammalian cells in 
culture is per se Well known. See, Jakoby and Pastan (eds.), 
Cell Culture. Methods in Enzymology, volume 58, Academic 
Press, Inc., Harcourt Brace Jovanovich, N.Y., (1979)). 
Examples of commonly used mammalian host cell lines are 
VERO and HeLa cells, Chinese hamster ovary (CHO) cells, 
and W138, BHK, and CQS cell lines, although it Will be 
appreciated by the skilled practitioner that other cell lines 
may be appropriate, e.g., to provide higher expression desir 
able glycosylation patterns, or other features. 
Clones are selected by using markers depending on the 
mode of the vector construction. The marker may be on the 
same or a different DNA molecule, preferably the same DNA 
molecule. In prokaryotic hosts, the transformant may be 
selected, e.g., by resistance to ampicillin, tetracycline or other 
antibiotics. Production of a particular product based on tem 
perature sensitivity may also serve as an appropriate marker. 
Prokaryotic or eukaryotic cells transformed With the 
nucleic acids of the present invention Will be useful not only 
for the production of the nucleic acids and proteins of the 
present invention, but also, for example, in studying the char 
acteristics of Par-4 proteins. 
Antisense nucleic acid sequences are useful in preventing 
or diminishing the expression of Par-4 genes, as Will be appre 
ciated by one skilled in the art. For example, nucleic acid 
vectors containing all or a fragment of Par-4 genes, comple 
mentary sequences of the former may be placed under the 
control of a promoter in an antisense orientation and intro 
duced into a cell. Expression of such an antisense construct 
Within a cell Will interfere With Par-4 transcription and/or 
translation and/ or replication. 
The probes and primers based on the Par-4 gene sequences 
disclosed herein are used to identify homologous Par-4 gene 
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sequences and proteins in other species. These Par-4 gene 
sequences and proteins are used in the diagnostic/prognostic, 
therapeutic and drug screening methods described herein for 
the species from Which they have been isolated. 
Expression and puri?cation of the Par-4 proteins of the 
invention can be performed essentially as outlined beloW. To 
facilitate the cloning, expression and puri?cation of mem 
brane and secreted protein a gene expression system, such as 
the pET System (Novagen), for cloning and expression of 
recombinant proteins in E. coli is selected. Also, a DNA 
sequence encoding a peptide tag, the His-Tap, is fused to the 
3' end of DNA sequences of interest to facilitate puri?cation 
of the recombinant protein products. The 3 end is selected for 
fusion to avoid alteration of any 5' terminal signal sequence. 
Nucleic acids chosen, for example, from the nucleic acids 
set forth in Table 2 for cloning the genes are prepared by 
polymerase chain reaction (PeR). Synthetic oligonucleotide 
primers speci?c for the 5 and 3 ends of the nucleotide 
sequences are designed and purchased from Life Technolo 
gies (Gaithersburg, Md.). All forWard primers (speci?c for the 
5' end of the sequence) are designed to include an Ncol 
cloning site at the 5' terminus. These primers are designed to 
permit initiation of protein translation at the methionine resi 
due encoded Within the Ncol site folloWed by a valine residue 
and the protein encoded by the DNA sequence. All reverse 
primers (speci?c for the 3' end of the sequence) include an 
EcoRI site at the 5' terminus to permit cloning of the sequence 
into the reading frame of the pET-28b. The pET-28b vector 
provides a sequence encoding an additional 20 carboxyl 
terminal amino acids including six histidine residues (at the 
C-terminus), Which comprise the histidine a?inity tag. 
Genomic DNA prepared from an individual as described in 
Example 1 is used as the source of template DNA for PCR 
ampli?cation (Ausubel et al., CurrentProtocols in Molecular 
Biology, John Wilty & Sons (1994)). To amplify a DNA 
sequence containing the nucleotide sequence, genomic DNA 
(50 ng) is introduced into a reaction vial containing 2 mM 
MgCl2, 1 micromolar synthetic oligonucleotide primers (for 
Ward and reverse primers) complementary to and ?anking a 
de?ned Par-4 region, 0.2 mM of each of deoxynucleotide 
triphosphate, dATP, dGTP, dCTP, dTTP and 2.5 units of heat 
stable DNA polymerase (Amplitaq, Roche Molecular Sys 
tems, lnc., Branchburg, NJ.) in a ?nal volume of 100 micro 
liters. 
Upon completion of thermal cycling reactions, each 
sample of ampli?ed DNA is puri?ed using the Qiaquick Spin 
PCR puri?cation kit (Qiagen, Gaithersburg, Md.). All ampli 
?ed DNA samples are subjected to digestion With the restric 
tion endonucleases, e.g., Ncol and EcoRI (NeW England 
BioLabs, Beverly, Mass., USA.) (Ausubel et al., Current 
Protocols in Molecular Biology, John Wiley & Sons, Inc. 
(1994)). DNA samples are then subjected to electrophoresis 
on 1.0% NuSeive (IFMC BioProducts, Rockland, Me.) aga 
rose gels. DNA is visualiZed by exposure to ethidium bromide 
and long Wave UV irradiation. DNA contained in slices iso 
lated from the agarose gel are puri?ed using the Bio 101 
GeneClean Kit protocol (Bio 101,V1sta, Calif.). 
The pET-28b vector is prepared for cloning by digestion 
With restriction endonucleases, e.g., Ncol and EcoRI (NeW 
England BioLabs, Beverly, Mass.) (Ausubel et al., Current 
Protocols in Molecular Biology, John Wiley & Sons, Inc. 
(1994)). The pET-28a vector, Which encodes the histidine 
a?inity tag that can be fused to the 5 end of an inserted gene, 
is prepared by digestion With appropriate restriction endonu 
cleases. 
Following digestion, DNA inserts are cloned (Ausubel et 
al., Current Protocols in Molecular Biology, John Wiley & 
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Sons, Inc. (1994)) into the previously digested pET-28b 
expression vector. Products of the ligation reaction are then 
used to transform the BL21 strain of E. coil (Ausubel et al., 
CurrentProtocols in MolecularBiology, John Wiley & Sons, 
Inc. (1994)) as described beloW. 
Competent bacteria, E. coli strain BL21 or E. coli strain 
BL21 (DE3), are transformed With recombinant pET expres 
sionplasmids carrying the cloned sequence according to stan 
dard methods (Ausubel et al., CurrentProtocols in Molecular 
Biology, John Wiley & Sons, Inc. (1994)). Brie?y, 1 micro 
liter of ligation reaction is mixed With 50 microliters of elec 
trocompetent cells and subjected to a high voltage pulse, after 
Which samples Were incubated in 0.45 ml SOC medium 
(0.5% yeast extract, 2.0% tryptone, 10 mM NaCl, 2.5 mM 
KC1, 10 mM MgC12, 10 mM MgSO4 and 20 mM glucose) at 
37° C. With shaking for 1 hour. Samples are then spread on LB 
agar plates containing 25 g/ml kanamycin sulfate for groWth 
overnight. Transformed colonies of BL21 are then picked and 
analyZed to evaluate cloned inserts, as described beloW. 
The pET vector can be propagated in any E. coil K-12 
strain, e.g., HNIS 174, HB101, JM109, DH5 and thelike, for 
purposes of cloning or plasmid preparation. Hosts for expres 
sion include E. coil strains containing a chromosomal copy of 
the gene for T7 RNA polymerase. These hosts are lysogens of 
bacteriophage DE3, a lambda derivative that carries the lad 
gene, the lacUV5 promoter and the gene for T7 RNA poly 
merase. T7 RNA polymerase is induced by addition of iso 
propyl-D-thiogalactoside (IPTG), and the T7 RNA poly 
merase transcribes any target plasmid containing a functional 
T7 promoter, such as pET-28b, carrying its gene of interest. 
Strains include, for example, BL21 (DE3) (Studier et al., 
Meth. Enzymol, 185260-89 (1990)). 
To express the recombinant sequence, 50 ng of plasmid 
DNA are isolated as described above to transform competent 
BL21 (DE3) bacteria as described above (provided by 
Novagen as part of the pET expression kit). The lacZ gene 
(-galactosidase) is expressed in the pET-System as described 
for the Par-4 recombinant constructions. Transformed cells 
Were cultured in SOC medium for 1 hour, and the culture is 
then plated on LB plates containing 25 ug/ml kanamycin 
sulfate. The folloWing day, the bacterial colonies are pooled 
and groWn in LB medium containing kanamycin sulfate (25 
ug/ml) to an optical density at 600 nM of 0.5 to 1.0 0D. units, 
at Which point 1 mM IPTG Was added to the culture for 3 
hours to induce 30 gene expression of the Par-4 recombinant 
DNA constructions. 
After induction of gene expression With IPTG, bacteria are 
collected by centrifugation in a Sorvall RC-3B centrifuge at 
3500><g for 15 minutes at 4° C. Pellets are resuspended in 50 
ml of cold mM Tris-HC1, pH 8.0, 0.1 M NaCl and 0.1 mM 
EDTA (STE buffer). Cells are then centrifuged at 2000><g for 
20 minutes at 4° C. Wet pellets are Weighed and froZen at —80° 
C. until ready for protein puri?cation. 
A variety of methodologies knoWn in the art can be used to 
purify the isolated proteins (Coligan et al., CurrentProtocols 
in Protein Science, John Wiley & Sons (1995)). For example, 
the froZen cells can be thaWed, resuspended in buffer and 
ruptured by several passages through a small volume microf 
luidiZer (Model M-1 105, Micro?uidics International Corp., 
NeWton, Mass.). The resultant homogenate is centrifuged to 
yield a clear supernatant (crude extract) and, folloWing ?ltra 
tion, the crude extract is fractioned over columns. Fractions 
are monitored by absorbance at OD280 nm and peak fractions 
may be analyZed by SDS-PAGE. 
The concentrations of puri?ed protein preparations are 
quanti?ed 15 spectrophotometrically using absorbance coef 
?cients calculated from amino acid content (Perkins, Eur J. 
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Biochem., 157:169-180 (1986)). Protein concentrations are 
also measured by the method of Bradford, Anal. Biochem., 
72:248-254 (1976) and LoWry et al., J. Biol. Chem., 193:265 
275 (1951) using bovine serum albumin as a standard. 
SDS-polyacrylamide gels of various concentrations are 
purchased from BioRad (Hercules, Calif.), and stained With 
Coomassie blue. Molecular Weight markers may include rab 
bit skeletal muscle myosin (200 kDa), E. coli-galactosidase 
(1 16 kDa), rabbit muscle phosphorylase B (97.4 kDa), bovine 
serum albumin (66.2 kDa), ovalbumin (45 kDa), bovine car 
bonic anyhdrase (31 kDa), soybean trypsin inhibitor (21.5 
kDa), egg White lysoZyme (14.4 kDa) and bovine aprotinin 
(6.5 kDa). Proteins can also be isolated by other conventional 
means of protein biochemistry and puri?cation to obtain a 
substantially pure product, i.e., 80, 95, or 99% free of cell 
component contaminants, as described in Jacoby, Methods in 
Enzymology, Vol. 104, Academic Press, NeW York (1984); 
Scoopes, Protein Puri?cation, Principles and Practice, 2'” 
Ed., Springer-Verlag, NeW York (1987); and Deutscher (ed.), 
Guide to Protein Puri?cation, Methods in Enzymology, Vol. 
182 (1990). If the protein is secreted, it can be isolated from 
the supernatant in Which the host cell is groWn; otherWise, it 
can be isolated from a lysate of the host cells. 
Once a su?icient quantity of the desired protein has been 
obtained, it may be used for various purposes. One use of the 
protein or polypeptide is the production of antibodies speci?c 
for binding. These antibodies may be either polyclonal or 
monoclonal, and may be produced by in vitro or in vivo 
techniques Well knoWn in the art. Monoclonal antibodies to 
epitopes of any of the peptides identi?ed and isolated as 
described can be prepared from murine hybridomas (Kohler, 
Nature, 25 6:495 (1975)). In summary, a mouse is inoculated 
With a feW micrograms of protein over a period of tWo Weeks. 
The mouse is then sacri?ced. The cells that produce antibod 
ies are then removed from the mouse’s spleen. The spleen 
cells are then fused With polyethylene glycol With mouse 
myeloma cells. The successfully fused cells are diluted in a 
microtiter plate and groWth of the culture is continued. The 
amount of antibody per Well is measured by immunoassay 
methods such as ELISA (Engvali, Meth. Enzymol, 70:419 
(1980)). Clones producing antibody can be expanded and 
further propagated to produce protein antibodies. Other suit 
able techniques involve in vitro exposure of lymphocytes to 
the antigenic polypeptides, or alternatively, to selection of 
libraries of antibodies in phage or similar vectors. See Huse et 
al., Science, 246:1275-128 1 (1989). For additional informa 
tion on antibody production see Davis et al., Basic Methods in 
MolecularBiology, Elsevier, N.Y., Section 21-2 (1989). Such 
antibodies are particularly useful in diagnostic assays for 
detection of variant protein forms, or as an active ingredient in 
a pharmaceutical composition. 
Example 1 
Construction of Par-4 Deletion Mutants 
pCB6+ vector, pCB6+Par-4, pCB6+_Zip and 163 (Par 
4DCTH) Were described previously (J ohnstone et al., (1996). 
pSV(gal Was a gift from Brett Spear, University of Kentucky. 
The RelA luciferase reporter system composed of Gal4 
luciferase (Gal4Luc) plasmid (that contains four Gal4 con 
sensus DNA binding sites derived from the Saccharomyces 
cerevisiae located upstream of luciferase reporter gene), and 
Gal4RelA plasmid (containing the yeast Gal4 DNA binding 
domain fused to the transactivation domain (TA1) of RelA) 
Were both from Dr. A. BaldWin (University of North Carolina 
at Chapel Hill, Chapel Hill, NC). The GFP cloning plasmids 
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pcDNA3.1/CTGFPTOPO and pcDNA3.1/NTGFPTOPO 
Were from Invitrogen Life Technologies, CA. 
Par-4 (SEQ ID NO: 1) as a template, followed by ligation 
in pcDNA3.1/CTGFPTOPO and then left in the GFP plasmid 
or digested With XbaI and KpnI and subcloned into pCB6+. 
Polyclonal antibodies for Par-4, NFkB (p65/RelA) and Fas 
Were obtained from Santa Cruz Biotechnology, Inc., Calif. 
The anti-GFP rabbit polyclonal Was from Torrey Pine 
Biolabs., CA. Terminal deoxynucleotide transferasemediated 
dUTPbiotin nick end labeling (TUNEL) enzyme and label 
Were purchased from Roche Molecular Biochemicals, IN. 
The propidium iodide Was from Clonetech, CA. and the 
Sepharose G protein Was from Amersham Pharmacia Bio 
tech., NJ. 
Example 2 
In vitro Activity of Par-4 Mutants on Cancer Cells 
Androgen independent prostate cancer cells PC3 or 
DUl45, androgen dependent prostate cancer cells LNCaP, 
normal primary prostatic cells PrE or PrS, NIH 3T3 ?broblast 
cells and NIH 3T3 Ras transformed ?broblast cells are knoWn 
in the art. Androgen dependent prostate cancer cells LAPC4 
Were from Charles SaWyers (University of California at Los 
Angeles, Calif.) and MDA PCa 2b Were from Nora Navone 
(MD. Anderson Cancer Center, Tex.). Androgen independent 
prostate cancer cells LNCaP IGFBP5, Which represent an 
isogenic derivative of LNCaP cells prepared by stable trans 
fection With IGFBP5 expression construct, Were provided by 
Martin Gleave (Vancouver General Hospital, British Colum 
bia, Canada). Immortalized human prostate epithelial cells 
PZHPV7, and the head and neck cancer cells SQ20B and 
SCC66 Were from Mansoor Ahmed, (University of Ken 
tucky). The human lung cancer cells A549, H157, H838 and 
H460 Were from John Yannelli (Internal Medicine Depart 
ment, University of Kentucky). The human breast cancer cells 
MCF7 and MDA 231 Were from GuoMin Li (Pathology, 
University of Kentucky). The immortalized breast epithelial 
cells MCFlOa Were from Johnson Lombardi (Georgetown 
University). Immortalized human endothelial cells HMEC 
Were from Mariana Karakashian (University of Kentucky). 
Cells Were transiently transfected With the indicated plas 
mid constructs by using lipofectamine plus (from Invitrogen 
Life Technologies, CA) folloWing the manufacturer’s proto 
col. Cells Were harvested after 48 hours, and Whole cell 
lysates Were subjected to Western blot analysis by using the 
Par-4 polyclonal antibody (from SantaCruz Biotechnology, 
Inc., CA), or luciferase and bgalactosidase assays as previ 
ously described) to quantify and normalize RelA activity. 
Cells Were transfected With the appropriate plasmid con 
struct. After ?xing they Were subjected to indirect immunof 
luorescence using secondary antibody conjugated With the 
?uorescent dye Alexa Fluor 488 (green) from Molecular 
Probes, Inc. For localization and apoptosis studies, nuclei 
Were stained With propidium iodide (PI) or 4',6' 
diamidino2phenylindole hydrochloride (DAPI) for 20 min 
utes after cell ?xation. 
Cells plated in chamber slides Were transiently transfected 
With untagged or GFP tagged Par-4 or its derivatives. Apop 
tosis Was determined by using TUNEL assay and DAPI stain 
ing. The cells expressing untagged protein Were visualized by 
staining With antiPar-4 antibody folloWed by DAPI staining. 
Apoptotic nuclei Were determined among transfected cells as 
described previously. 
The results indicate that nuclear translocation of Par-4 
correlates With susceptibility to apoptosis. Previous immuno 
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histochemical studies localized Par-4 to both the cytoplasm 
and nucleus of prostate cells but exclusively to the cytoplasm 
of most tissues and nonprostatic cells. To determine the pre 
cise relationship betWeen Par-4 localization and the induction 
of apoptosis, a broad panel of transformed and non-trans 
formed cells Was transiently transfected With GFPPar-4 or 
GFP vector for control, and the transfectants Were studied for 
intracellular localization of Par-4 or apoptosis by confocal 
microscopy. These experiments included NIH 3T3 Ras, PC3 
and DUl45 that Were previously shoWn to be sensitive apo 
ptosis induction by Par-4; LNCaP, PrE, PrS and NIH 3T3 
parental cells that Were resistant to Par-4; and LNCaP 
IGFBP5 (an isogenic derivative of LNCaP), MDA MB2b, 
and LAPC4 that had not been previously tested. Representa 
tive examples of nuclear versus cytoplasmic expression and 
susceptibility to apoptosis are shoWn in FIG. 1 (A and B). It 
Was noted that Par-4 nuclear presence correlated With its 
ability to induce apoptosis (See FIG. 1 and Table 1). Par-4 Was 
detected in the nucleus and cytoplasm in androgen indepen 
dent prostate cancer cells PC3, DUl45, LNCaP derived cells 
LNCaP/IGFBPS, and Rastransformed NIH 3T3 cells. All of 
these cell lines Were also sensitive to apoptosis induction by 
Par-4 (See Table 1, FIG. 1). HoWever, Par-4 Was strictly 
cytoplasmic in the apoptosis-resistant androgen dependent 
prostate cancer cells LNCaP, LAPC4 and MDA 2b, mouse 
immortalized ?broblast NIH 3T3 cells, and primary prostate 
epithelial cells PrE or primary prostate stromal cells PrS (See 
Table 1). Coexpression of dominant negative FADD or RelA, 
Which inhibits Par-4 induced apoptosis, did not prevent Par-4 
from translocation to the nucleus, suggesting that nuclear 
entry preceded apoptosis by Par-4. 
It Was discovered that NLS2, but not NLS 1, is essential for 
nuclear entry. The 332 amino acid protein Par-4 has tWo 
putative nuclear localization sequences, NLSl (amino acid 
2025) and NLS2 (amino acid 137153) that are conserved in 
human, rat and mouse Par-4. To delineate the relationship 
betWeen Par-4 entry into the nucleus and induction of apop 
tosis, Par-4 derivatives Were prepared that lacked the NLS 
sequences (See FIG. 2A). PC3 cells Were transiently trans 
fected With these constructs and examined for nuclear entry, 
inhibition of NFkB transcription activity or apoptosis. Con 
structs DNLSl shoWed nuclear entry, Whereas DNLS2, 
Which lacked an intact NLS2 domain, failed to translocate to 
the nucleus. This suggests that NLS2 is a functional nuclear 
localization sequence. Moreover, loss of DNLS2 but not 
DNLSl abrogated the ability of Par-4 to inhibit NFkB tran 
scription activity and induce apoptosis in PC3 cells (See FIG. 
2B). These ?ndings indicated that an intact NLS2 sequence 
Was essential for nuclear entry of Par-4, and that the ability to 
inhibit NFkB transcription activity and to induce apoptosis 
correlated With nuclear entry of Par-4. 
The leucine zipper domain of Par-4 is not essential for 
apoptosis. Other domains of Par-4 Were sought Which are 
essential for apoptosis. The C-terminal leucine zipper domain 
of Par-4 is required for sensitization of Par-4 resistant cells to 
apoptosis and for binding to all currently knoWn partners of 
Par-4 including WT1, zPKC, p62 and Dlk. Transient trans 
fection of a mutant lacking the leucine zipper domain (DZip) 
in PC3 cells resulted in direct induction of apoptosis (See 
FIG. 3E.) To further characterize the C-terminus of Par-4, 
various C-terminal deletion mutants Were prepared and stud 
ied for nuclear localization, inhibition of NFkB transcription 
activity and apoptosis in PC3 cells. All C-terminal mutants of 
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Par-4 had a tendency to translocate preferentially to the 
nucleus (See FIG. 3B), Which suggests that the leucine zipper 
domain itself may prevent the nuclear translocation of the 
protein. As seen in FIGS. 3C and 3D), NFkB transcription 
activity and apoptosis Were differentially affected by the 
extent of the C-terminal deletions. Par-4 mutants DZip and 
1204 inhibited NFkB transcription activity and induced apo 
ptosis. HoWever, mutants 1185 and 1163 neither inhibited 
NFkB transcription activity nor did they induce apoptosis. 
Moreover, the ability to induce Fas tra?icking to the cell 
membrane in these mutants correlated With their ability to 
induce apoptosis. These experiments indicated that the amino 
acids doWnstream of 204, including the leucine zipper 
domain, Were dispensable for apoptosis by Par-4, and that 
binding to the partner proteins via the leucine zipper domain 
Was not essential for apoptosis induction or inhibition of 
NFkB transcriptional activity by Par-4. 
Example 3 
Identi?cation of the Core Domain of Par-4 
Previously, NLS2 Was identi?ed as the most critical 
sequence for nuclear localization and apoptosis induction. To 
further con?rm the importance of NLS2, tWo N-terminal 
deletion constructs 137332 Were constructed and 148332 
With either an intact NLS2 or a disrupted NLS2, respectively 
(See FIG. 4A). When PC3 cells Were transfected With these 
constructs, 137332 but not 148332, Was translocated to the 
nucleus (See FIG. 4B) and induced apoptosis. This suggested 
that NLS2 Was critical for Par-4 function, and that the N-ter 
minus of Par-4 Was not required for Par-4 nuclear entry and 
apoptotic functions. 
To de?ne the minimal domain of Par-4 essential for apop 
tosis, additional constructs Were made that began With the 
intact NLS2 domain at the amino terminus and With various 
deletions upstream of amino acid 204 (FIG. 4C). Transient 
transfection of PC3 cells indicated that 137195, but not 
137190, inhibited NFkB transcription activity and induced 
apoptosis (See FIGS. 4D and 4E). Moreover, co-transfection 
of 137195 With dnFADD inhibited apoptosis (See FIG. 4G), 
indicating that similar to full length Par-4, the 137195 core 
domain induced apoptosis by activation of the Fas prodeath 
pathWay together With inhibition of NFkB transcriptional 
activity. Thus, these ?ndings identi?ed 137195 as the mini 
mal core domain of Par-4 that Was essential and suf?cient to 
induce apoptosis in PC3 cells. 
The core domain of Par-4 induces apoptosis speci?cally in 
cancer cells but not in normal cells. To determine Whether 
similar to Par-4, the core domain 137195 induced apoptosis 
exclusively in androgen independent prostate cancer cells, a 
panel of androgen dependent or independent prostate cancer 
cells and primary normal cells Were tested. 137195 induced 
apopto sis in both androgen independent and dependent pros 
tate cancer cells but not in normal cells (See FIG. 5A). These 
data suggested the presence of an inhibitory domain in the 
C-terminus of Par-4 and that its deletion alloWed 137195 to be 
functional in cells resistant to the apoptotic action of full 
length Par-4. In vieW of this expanded target range of 137195, 
the susceptibility of a broad panel of cancer and primary 
normal or immortalized cells to apoptosis by Par-4 or 137195 
Were studied, by using 137190 as a control. These experi 
ments indicated that both Par-4 susceptible and Par-4 resis 
tant cancer cells, regardless of Whether or not they Were of 
prostatic origin, Were induced to undergo apoptosis by 
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137195 but not by 137190 (See Table 2). Neither Par-4 nor 
137195 induced apoptosis in the primary normal or immor 
talized cells (See Table 2). 
TABLE 1 
Correlation between nuclear translocation and susceptible to 
apoptosis by Par-4. 
Nuclear Cytoplasmic Apoptosis by 
Cells Par-4 Par-4 Par-4 
androgen- PC-3 + + Sensitivel7 
DU145 + — Sensitive 
LNCaP + + Sensitive 
androgen- LNCaP — + ResistantC 
MDA MB2b — + Resistant 
LAPC-4 — + Resistant 
immortalized PZ-HPV-7 — + Resistant 
primary PrE — + Resistant 
primary PrS — + Resistant 
immortalized NIH 3T3 — + Resistant 
transformed NIH 3T3 + + Sensitive 
“LNCaP IGFBP5 is an isogenic derivative ofLNCaP cells. 
bSensitive: 50-75% ofthe transfected cells undergo apoptosis. 
L‘Resistant: <10% ofthe transfected cells undergo apoptosis. 
TABLE 2 
137-195 mutant selectively kills cancer cells. 
Apoptosis Apoptosis Apoptosis 
Sensitive to PC-3 
DU145 
LNCaP 
MDA MB 
HMECd - 
LNCaP — 
LAPC-4 — 
MDA 2b — 
MCF-7f - 
PA-HPV-7 — 
PrS — 
PrE — 
MCFl Oag — 
Cancer 
Cells |+++ 
Resistant to |+++++++++ l Immor- Resistant to 
talized 
‘1 + re?ects apoptosis in 50-75% ofthe transfected cells. 
b + re?ects apoptosis in 25-35% ofthe transfected cells. 
C — re?ects apoptosis in <10% ofthe transfected cells for all the constructs regardless ofthe 
cancer or normal cell background. 
uman microvascular endothelial cells. 
Eestrogen-independent breast cancer cell line. 
festrogen-dependent breast cancer cell line. 
gimmortalized breast epithelial cell lines. 
While this invention has been particularly shoWn and 
described With references to preferred embodiments thereof, 
it Will be understood by those skilled in the art that various 
changes in form and details may be made therein Without 
departing from the spirit and scope of the invention as de?ned 
by the appended claims. 
All references discussed above are herein incorporated by 
reference in their entirety. 
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SEQUENCE LISTING 
<l60> NUMBER OF SEQ ID NOS: 1 
<2lO> SEQ ID NO 1 
<211> LENGTH: 332 
<2l2> TYPE: PRT 
<2l3> ORGANISM: Rattus norvegicus 
<400> SEQUENCE: 1 
Met Ala Thr Gly Gly Tyr Arg Ser Ser Gly Ser Thr Thr Asp Phe Leu 
1 5 1O 15 
Leu Trp Lys Ala Lys Arg Glu Lys Met Arg Ala Lys Gln Asn Pro Val 
Gly Pro Gly Ser Ser Gly Gly Asp Pro Ala Ala Lys Ser Pro Ala Gly 
35 4O 45 
Pro Leu Ala Gln Thr Thr Ala Ala Gly Thr Ser Glu Leu Asn His Gly 
50 55 60 
Pro Ala Gly Ala Ala Ala Pro Ala Ala Pro Gly Pro Gly Ala Leu Asn 
65 7O 75 8O 
Cys Ala His Gly Ser Ser Ala Leu Pro Arg Gly Ala Pro Gly Gly Ser 
85 9O 95 
Arg Arg Pro Glu Asp Glu Cys Pro Ile Ala Ala Gly Ala Ala Gly Ala 
100 105 110 
Pro Ala Ser Arg Gly Asp Glu Glu Glu Pro Asp Ser Ala Pro Glu Lys 
115 120 125 
Gly Arg Ser Ser Gly Pro Ser Ala Arg Lys Gly Lys Gly Gln Ile Glu 
130 135 140 
Lys Arg Lys Leu Arg Glu Lys Arg Arg Ser Thr Gly Val Val Asn Ile 
145 150 155 160 
Pro Ala Ala Glu Cys Leu Asp Glu Tyr Glu Asp Asp Glu Ala Gly Gln 
165 170 175 
Lys Glu Arg Lys Arg Glu Asp Ala Ile Thr Gln Gln Asn Thr Ile Gln 
180 185 190 
Asn Glu Ala Ala Ser Leu Pro Asp Pro Gly Thr Ser Tyr Leu Pro Gln 
195 200 205 
Asp Pro Ser Arg Thr Val Pro Gly Arg Tyr Lys Ser Thr Ile Ser Ala 
210 215 220 
Pro Glu Glu Glu Ile Leu Asn Arg Tyr Pro Arg Thr Asp Arg Ser Gly 
225 230 235 240 
Phe Ser Arg His Asn Arg Asp Thr Ser Ala Pro Ala Asn Phe Ala Ser 
245 250 255 
Ser Ser Thr Leu Glu Lys Arg Ile Glu Asp Leu Glu Lys Glu Val Leu 
260 265 270 
Arg Glu Arg Gln Glu Asn Leu Arg Leu Thr Arg Leu Met Gln Asp Lys 
275 280 285 
Glu Glu Met Ile Gly Lys Leu Lys Glu Glu Ile Asp Leu Leu Asn Arg 
290 295 300 
Asp Leu Asp Asp Met Glu Asp Glu Asn Glu Gln Leu Lys Gln Glu Asn 
305 310 315 320 
Lys Thr Leu Leu Lys Val Val Gly Gln Leu Thr Arg 
325 330 
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I claim: 
1. An isolated rat prostate apoptosis responsive 4 (Par-4) 
protein fragment selected from the group consisting of amino 
acids 1-204, 137-221, 137-213, 137-198 and 137-195 of the 
Par-4 protein (SEQ ID NO: 1) Wherein the Par-4 protein 5 
fragment is effective in reducing the siZe of tumors resistant to 
apoptosis by Par-4. 
2. A method of producing a polypeptide, comprising incu 
bating a host cell comprising a nucleic acid encoding the 
Par-4 protein fragment of claim 1 in operable linkage With a 
promoter under conditions that permit expression of the Par-4 
protein fragment. 
24 
3. An isolated fusion polypeptide comprising a Par-4 frag 
ment selected from the group consisting of amino acids 
1-204,137-221,137-213,137-198 and 137-195 ofPar-4 pro 
tein (SEQ ID NO: 1). 
4. A pharmaceutical composition for the treatment of can 
cer, comprising an isolated and puri?ed Par-4 protein selected 
from the group consisting of amino acids 1-204, 137-221, 
137-213, 137-198 and 137-195 ofthe Par-4 protein (SEQ ID 
NO: 1), and a pharmaceutically acceptable diluent, carrier or 
10 excipient. 
